BACKGROUND AND PURPOSE We used radiomic analysis to establish a radiomic signature based on anatomical magnetic resonance imaging (MRI) sequences and explore its effectiveness as a novel prognostic biomarker for skull base chordoma (SBC). MATERIALS AND METHODS In this retrospective study, radiomic analysis was performed using preoperative axial T1 FLAIR, T2-weighted, and enhanced T1 FLAIR from a single hospital. The primary clinical endpoint was progression-free survival. A total of 1860 3-D radiomic features were extracted from manually segmented region of interest. Pearson correlation coefficient was used for feature dimensional reduction and a ridge regression-based Cox proportional hazards model was used to determine a radiomic signature. Afterwards, radiomic signature and nine other potential prognostic factors, including age, gender, histological subtype, dural invasion, blood supply, adjuvant radiotherapy, extent of resection, preoperative KPS, and postoperative KPS were analyzed to build a radiomic nomogram and a clinical model. Finally, we compared the nomogram with each prognostic factor/model by DeLong's test. RESULTS A total of 148 SBC patients were enrolled, including 64 with disease progression. The median follow-up time was 52 months (range 4-122 months). The Harrell's concordance index of the radiomic signature was 0.745 (95% CI, 0.709-0.781) for the validation cohort, and its discrimination accuracy in predicting progression risk at 5 years in the same cohort was 82.4% (95% CI, 72.6-89.7%). CONCLUSIONS The radiomics is a low-cost, non-invasive method to predict SBC prognosis preoperatively. Radiomic signature is a potential prognostic biomarker that may allow the individualized evaluation of patients with SBC.

中文翻译：

---

放射组学特征：一种基于磁共振成像的新型颅底脊索瘤患者预后生物标志物

背景和目的 我们使用放射组学分析建立基于解剖磁共振成像 (MRI) 序列的放射组学特征，并探索其作为颅底脊索瘤 (SBC) 新型预后生物标志物的有效性。材料和方法 在这项回顾性研究中，使用来自一家医院的术前轴向 T1 FLAIR、T2 加权和增强 T1 FLAIR 进行放射组学分析。主要临床终点是无进展生存期。从手动分割的感兴趣区域中提取了总共 1860 个 3-D 放射组学特征。Pearson 相关系数用于特征降维，基于岭回归的 Cox 比例风险模型用于确定放射组学特征。之后，放射学特征和其他九个潜在的预后因素，包括年龄、性别、分析组织学亚型、硬脑膜侵犯、血供、辅助放疗、切除范围、术前KPS和术后KPS，建立放射线列线图和临床模型。最后，我们通过 DeLong 检验将列线图与每个预后因素/模型进行了比较。结果共纳入 148 名 SBC 患者，其中 64 名出现疾病进展。中位随访时间为 52 个月（范围 4-122 个月）。验证队列的放射组学特征的 Harrell 一致性指数为 0.745（95% CI，0.709-0.781），其在同一队列中预测 5 年进展风险的辨别准确率为 82.4%（95% CI，72.6-89.7） %）。结论放射组学是一种低成本、无创的术前预测 SBC 预后的方法。